Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation.

Area of Science:

• Cell Biology
• Genetics
• Biochemistry

Background:

• Mitochondrial DNA (mtDNA) mutations lead to debilitating disorders with no effective treatments.
• Mitophagy, the selective degradation of mitochondria via autophagy, is crucial for maintaining mitochondrial health.
• Inhibiting the mammalian target of rapamycin (mTOR) kinase activates mitophagy.

Purpose of the Study:

• To investigate if enhancing mitophagy can reduce levels of a specific mtDNA mutation.
• To test the therapeutic potential of rapamycin in a cellular model of Leber's hereditary optic neuropathy.

Main Methods:

• Used a human cybrid cell line with a heteroplasmic mtDNA G11778A mutation.
• Treated cells with rapamycin to inhibit mTORC1/S6 kinase signaling.
• Assessed mitophagy, mutation levels, ATP production, and cell viability.

Main Results:

• Rapamycin treatment increased mitophagy, evidenced by mitochondrial colocalization with autophagosomes and increased autophagic vacuoles.
• A significant progressive decrease in the G11778A mtDNA mutation level was observed.
• Partial restoration of ATP levels and no significant increase in cell death or mtDNA depletion occurred.

Conclusions:

• Pharmacological inhibition of mTOR by rapamycin activates mitophagy, driving selection against mutated mtDNA.
• This strategy shows promise for treating mitochondrial disorders caused by heteroplasmic mtDNA mutations.
• Further research is needed to confirm efficacy across different mutations and cell types.